The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IASLC TTLC 2022 | Immunotherapy as combination and neoadjuvant therapies in NSCLC
Jay Lee, MD, University of California, Los Angeles, CA, discusses the role of immunotherapies in various settings to treat non-small cell lung cancer (NSCLC). Multiple trials including the Phase III CheckMate 816 trial (NCT02998528) of ipilimumab or nivolumab with chemotherapy have demonstrated the superiority of combining checkpoint inhibitors with chemotherapy, especially in stage II/II lung cancer. Whilst the use of adjuvant immunotherapy still remains under investigation, neoadjuvant immunotherapy has proven to be effective, with data from the IMpower010 (NCT02486718) and KEYNOTE-091 (NCT02504372) trials assessing atezolizumab and pembrolizumab respectively. This interview took place at the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC 2022).
